Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARA NYSE:DVA OTCMKTS:HEMA NASDAQ:PGNY NASDAQ:TVTY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsDVADaVita$129.27+1.0%$132.02$122.93▼$179.60$9.15B1.13605,763 shs699,234 shsHEMAHemaCare$25.31+0.6%$25.31$8.62▼$26.23$346.52M1.4739,950 shs5,400 shsPGNYProgyny$19.49-0.1%$21.71$13.39▼$26.76$1.68B1.341.75 million shs840,739 shsTVTYTivity Health$32.50$32.50$21.25▼$32.89$1.62B2.14820,051 shs1,170 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%DVADaVita+1.00%+2.76%-3.28%-10.87%-20.59%HEMAHemaCare0.00%0.00%0.00%0.00%0.00%PGNYProgyny-0.05%+0.78%-10.18%-15.66%+22.89%TVTYTivity Health0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsDVADaVita$129.27+1.0%$132.02$122.93▼$179.60$9.15B1.13605,763 shs699,234 shsHEMAHemaCare$25.31+0.6%$25.31$8.62▼$26.23$346.52M1.4739,950 shs5,400 shsPGNYProgyny$19.49-0.1%$21.71$13.39▼$26.76$1.68B1.341.75 million shs840,739 shsTVTYTivity Health$32.50$32.50$21.25▼$32.89$1.62B2.14820,051 shs1,170 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%DVADaVita+1.00%+2.76%-3.28%-10.87%-20.59%HEMAHemaCare0.00%0.00%0.00%0.00%0.00%PGNYProgyny-0.05%+0.78%-10.18%-15.66%+22.89%TVTYTivity Health0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAAmerican Renal Associates 0.00N/AN/AN/ADVADaVita 1.80Reduce$153.2518.55% UpsideHEMAHemaCare 0.00N/AN/AN/APGNYProgyny 2.70Moderate Buy$25.4430.55% UpsideTVTYTivity Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DVA, PGNY, TVTY, HEMA, and ARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025DVADaVitaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/14/2025DVADaVitaTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$140.0010/9/2025DVADaVitaBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$160.00 ➝ $149.0010/8/2025DVADaVitaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025PGNYProgynyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025DVADaVitaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025PGNYProgynyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/10/2025DVADaVitaBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderperform$145.00 ➝ $140.008/26/2025PGNYProgynyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $25.008/20/2025PGNYProgynyCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$21.00 ➝ $23.008/8/2025DVADaVitaTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$148.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAAmerican Renal Associates$822.52M0.48$1.69 per share6.80$2.59 per share4.45DVADaVita$12.82B0.72$19.32 per share6.69$4.83 per share26.76HEMAHemaCareN/AN/AN/AN/AN/AN/APGNYProgyny$1.24B1.35$0.34 per share56.51$4.96 per share3.93TVTYTivity Health$481.25M3.37$1.95 per share16.70$2.39 per share13.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAAmerican Renal Associates-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/ADVADaVita$936.34M$10.1712.7110.170.926.35%369.39%4.62%10/29/2025 (Estimated)HEMAHemaCareN/AN/A0.00∞N/AN/AN/AN/AN/APGNYProgyny$54.34M$0.5933.0329.981.664.28%10.69%7.12%11/6/2025 (Estimated)TVTYTivity Health$104.91M$1.7119.0116.411.8217.25%75.94%13.65%N/ALatest DVA, PGNY, TVTY, HEMA, and ARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PGNYProgyny$0.37N/AN/AN/A$299.23 millionN/A10/29/2025Q3 2025DVADaVita$3.29N/AN/AN/A$3.43 billionN/A8/7/2025Q2 2025PGNYProgyny$0.42$0.19-$0.23$0.19$315.70 million$332.87 million8/5/2025Q2 2025DVADaVita$2.70$2.95+$0.25$2.58$3.36 billion$3.38 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAAmerican Renal AssociatesN/AN/AN/AN/AN/ADVADaVitaN/AN/AN/AN/AN/AHEMAHemaCareN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ATVTYTivity HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAAmerican Renal Associates7.541.051.02DVADaVitaN/A1.391.34HEMAHemaCareN/AN/AN/APGNYProgynyN/A2.702.70TVTYTivity Health2.972.472.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAAmerican Renal Associates78.42%DVADaVita90.12%HEMAHemaCareN/APGNYProgyny94.93%TVTYTivity Health91.54%Insider OwnershipCompanyInsider OwnershipARAAmerican Renal Associates9.50%DVADaVita1.50%HEMAHemaCare26.20%PGNYProgyny9.40%TVTYTivity Health2.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAAmerican Renal Associates4,97734.54 millionN/AOptionableDVADaVita76,00071.50 million70.43 millionOptionableHEMAHemaCareN/A13.69 millionN/ANot OptionablePGNYProgyny31085.98 million77.90 millionOptionableTVTYTivity Health38049.93 million48.92 millionOptionableDVA, PGNY, TVTY, HEMA, and ARA HeadlinesRecent News About These CompaniesTivity Health, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 20, 2025 Deadline to file Lead Plaintiff MotionJuly 25, 2025 | globenewswire.comTivity Health names CEOJuly 16, 2025 | nashvillepost.comNTivity Health names new CEO, taps former Aetna executive for boardJuly 16, 2025 | bizjournals.comTivity Health Appoints Natasha Deckmann as CEOJuly 15, 2025 | globenewswire.comTivity Health, Investors Reach Tentative Settlement Over MergerMay 22, 2025 | news.bloomberglaw.comNTivity Must Face Investor Claims Over Nutrisystem AcquisitionApril 24, 2025 | news.bloomberglaw.comNTivity Health has your back – especially as you ageOctober 24, 2024 | koin.comKTivity Health Reports Fewer Falls, Higher Rates of Exercise for Medicare Advantage MembersSeptember 11, 2024 | finance.yahoo.comTivity Health Denied Immediate Appeal Over Investor Class StatusSeptember 10, 2024 | news.bloomberglaw.comN10 Foods for Thyroid Health—And 3 To AvoidMarch 12, 2024 | health.comHTivity Health Appoints Hill Ferguson as President and CEOJuly 6, 2023 | finance.yahoo.comFranklin-based health care company names new CEOJuly 6, 2023 | bizjournals.comTivity CEO moves to Amedisys top spotMarch 14, 2023 | nashvillepost.comNTVTY.OFebruary 24, 2023 | reuters.comTivity Health acquires Pikesville’s Burnalong in a ‘growth investment’February 16, 2023 | technical.lyTTivity Health buys digital health and wellness platform BurnalongFebruary 1, 2023 | bizjournals.comTivity Health Acquires Industry Leading Digital Health and Wellness Platform BurnalongJanuary 31, 2023 | finance.yahoo.comTivity Health has tips to prevent falls with Silver SneakersOctober 11, 2022 | news.yahoo.comTVTY.OQSeptember 28, 2022 | reuters.comWholeHealth Living to Partner with Vori Health to Provide Industry Leading Musculoskeletal SolutionSeptember 6, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAMD Could Double From Here—Thanks to Its Blockbuster OpenAI DealBy Thomas Hughes | October 7, 2025Why Wall Street Is Betting Billions on Oklo's Nuclear VisionBy Jeffrey Neal Johnson | September 26, 2025Conagra Brands High-Yield and Deep Value Are a Buy in OctoberBy Thomas Hughes | October 3, 2025Advanced Micro Devices Eyes $300 as AI Demand SurgesBy Thomas Hughes | October 16, 2025This AI Chip Giant Could Be the Market’s Next Big WinnerBy Gabriel Osorio-Mazilli | October 17, 2025DVA, PGNY, TVTY, HEMA, and ARA Company DescriptionsAmerican Renal Associates NYSE:ARAAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.DaVita NYSE:DVA$129.26 +1.25 (+0.97%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$126.95 -2.31 (-1.79%) As of 10/24/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.HemaCare OTCMKTS:HEMA$25.31 +0.15 (+0.60%) As of 01/3/2020HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.Progyny NASDAQ:PGNY$19.49 -0.01 (-0.05%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$19.35 -0.14 (-0.72%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Tivity Health NASDAQ:TVTYTivity Health, Inc. provides fitness and health products and solutions in the United States. The company offers SilverSneakers to members of Medicare Advantage, Medicare Supplement, and group retiree plans; Prime Fitness, a fitness facility access program through commercial health plans, employers, and other sponsoring organizations; virtual fitness experiences, including live instructor-led classes; and WholeHealth living program, a continuum of services related to complementary, alternative, and physical medicine. It also provides Wisely Well brand meals designed to support individuals and caregivers who are seeking meal convenience, as well as those recovering after a hospitalization or living with chronic conditions. The company was formerly known as Healthways, Inc. and changed its name to Tivity Health, Inc. in January 2017. Tivity Health, Inc. was incorporated in 1981 and is headquartered in Franklin, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
